



BPH Corporate Ltd

BPH Corporate [ASX: BPH] ASX Announcement

26 July 2010

Companies Announcements Office
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
Sydney NSW 2000

BPH TO ENGAGE IN MELANOMA DRUG DISCOVERY

BPH Corporate Limited (BPH) is pleased to announce that Principal Researcher Dr Robin Scaife has been awarded funding from the Scott Kirkbride Melanoma Research Centre (SKMRC) to spearhead a melanoma drug discovery programme at the Western Australian Institute for Medical Research (WAIMR). The one year discovery grant was presented to Dr Scaife at the annual SKMRC fundraising luncheon.

The SKMRC supports research that is aimed at providing crucial breakthroughs for improved diagnosis and treatment of melanomas and was established in 2005 in memory of Perth golfer, Scott Kirkbride, who lost his battle with this disease in 2004 at the age of 27.

Although melanomas have a reputation for being particularly refractory to therapeutic intervention, some types of melanoma have recently been shown to respond well to a new class of customized cancer drugs. Dr Scaife and his collaborators at WAIMR and the University of Western Australia, will use the high-content imaging and analysis platform at Molecular Discovery Systems to screen an arsenal of new drug-like molecules for inhibitors of melanoma cell survival and proliferation.

Yours sincerely,

David Breeze
Chairman

For more information contact:

Mr David Breeze
BPH Corporate Limited
Tel : +61 8 9328 8366